Co-Dergocrine Mesylate: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Age-Related Cognitive Decline

Drugs & Aging

Volumn 2, Issue 3, 1992, Pages 153-173

  Wadworth, Alison N ^a   Chrisp, Paul ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTOXINE;

AGING; ANIMAL; COGNITIVE DEFECT; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW;

AGING; ANIMAL; COGNITION DISORDERS; ERGOLOID MESYLATES; HUMAN;

EID: 0026858998     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199202030-00002     Document Type: Article

References (116)

1. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man
2. Cognition and Aging
3. Muscarinic cholinergic receptors in the hippocampus of the aged rat: effects of long-term hydergine administration
4. Effect of long term hydergine treatment on the age-dependent loss of mossy fibers and of granule cells in the rat hippocampus
5. Influence of treatment on symptomatology and correlated elec-troencephalographic (EEG) changes in the aged
6. Hydergine in Alzheimer’s disease
7. Comparative study of suloctidil and dihydroer-gotoxine in chronic cerebrovascular insufficiency. Results of a double blind double dummy multicentric trial
8. Avaliaçao da eficacia clínica do buflomedil no tratamento de pacientes portadores de arterisosclerose senil
9. Clinical trial with amantadine and Hydergine in elderly patients
10. An ergot alkaloid preparation (Hydergine) versus papaverine in treating common complaints of the aged: double-blind study
11. Evaluation of the efficacy and tolerability of dihydroergotoxine and alpha-methyldopa for the treatment of elderly hypertensives with CSCI
12. Epidemiological aspects of dementia and considerations in planning services
13. The effect of chronic Hydergine treatment on the plasticity of synaptic junctions in the dentate gyrus of aged rats
14. Insuficiencia vasculo-encefalica cronica. Ensayo terapeutico
15. The EEG response to intravenous dihydroergotoxine mesylate
16. Neurotransmitters in old age and dementia
17. Implications of long-term study of Hydergine in elderly patients with chronic senile cerebral insufficiency
18. Acetylcholine, glutamate, GABA and neuropeptides in senile dementia of Alzheimer type
19. Alzheimer’s disease: new developments in treatment and symptom management research. Pharmacotherapy of cognitive deficits in Alzheimer’s disease and age-associated memory impairment
20. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change — report of a National Institute of Mental Health group
21. Dementia
22. Behavioral and neurochemical effects of Hydergine in rats
23. Cholinergic strategies in the treatment of Alzheimer’s disease
24. Sinus bradycardia following treatment with hydergine for cerebrovascular insufficiency
25. Estudo epidemiológico da insufficiência cerebral senil e resposta terapêutica à di-hid-roergotoxina com avaliaçāo pela escala SCAG
26. Comparative longterm study of dihydroergotoxine and cinnarizine effects on incipient dementia syndrome. Abstract
27. Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: effect of chronic Hydergine treatment
28. Bio-pharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability
29. Hydergine effect on polactin and reaction time in dementia
30. The actions of Hydergine® on the brain
31. Dihydroergotoxine in senile cerebral insufficiency
32. Cognitive decline in advanced age: future directions for the psychometric differentiation of normal and pathological age changes in cognitive function
33. Hydergine enhances memory in mice
34. The metabolism of monoamines and their etiological importance in aging and in patients with dementia of Alzheimer type
35. Rationale for the use of therapeutic agents in affective disorders (AD) and senile dementia of the alzheimer type (SDAT)
36. Effect of ergot alkaloids on serum prolactin in non-psychotic organic brain syndrome of the elderly
37. Comparative randomised study of cerebral blood flow after long-term administration of pentoxifylline and co-dergocrine mesylate in patients with chronic cerebrovascular disease
38. The effects of an ergot-alkaloid derivative (Hydergine) on aspects of psychomotor performance, arousal, and cognitive processing ability
39. Pharmaceutical treatment of patients with senile brain changes
40. Response of geriatric patients from the satellite nursing homes of Maricopa county to Hydergine® therapy: a double-blind study
41. Psychiatric disorders
42. Alzheimer’s disease: is it worth treating?
43. Effects of pyritinol-HCl on blood flow and oxidative metabolism of the brain in patients with dementia
44. Effects of long-term ergoloid mesylates (Hydergine®) administration in healthy pensioners: 5-year results
45. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature
46. Pharmaco-cinetique de deux derives ergotes: la dihydroergotoxine et la dihydroergotamine. Biodisponibilite comparative de differentes formulations par rapport aux formes solutions
47. The uptake of DH-ergotoxine by different parts of the cat brain
48. Central monoaminergic neurons: single-unit studies in behaving animals
49. The treatment of senile dementia associated with cerebrovascular insufficiency: a comparative study of buflomedil and dihydrogenated ergot alkaloids
50. Reversal of anisomycin-induced amnesia by the ergot derivative Hydergine
51. Effects of twice standard dosage of neuroactive drugs in dementia: a preliminary report
52. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners; results after 3 years
53. Electroencephalographic and psychometric measurements during treatment of cerebral insufficiency with nicergoline and dihydroergotamine mesilate
54. Hydergine pharmacokinetics in the elderly
55. Multicenter double-blind placebo-controlled long term clinical trial of Hydergine® in chronic senile cerebral insufficiency: an interim report
56. Learning and haemodynamic and metabolic concomitants in aged animals after an ischemia
57. Neuropharmacology of bromocriptine and dihydroergotoxine (Hydergine®)
58. Hydergine® in senile mental impairment
59. Hydergine: interaction with neurotransmitter systems in the central nervous system
60. Dopamine receptor profile of co-dergocrine (Hydergine®) and its components
61. Interaction of ergot alkaloids and their combination (co-dergocrine) with α-adrenoceptors in the CNS
62. Some correlations in geriatric patients between EEG parameters and clinical status as evaluated using the observer-rated SCAG rating scale
63. Electroencephalo-graphic and clinical changes as correlated in geriatric patients treated three months with an ergot alkaloid preparation
64. Hydergine: a review of 26 clinical studies
65. Neurochemistry of the aging brain and senile dementia
66. Effects of prolonged co-dergocrine mesylate (Hydergine®) treatment on local cerebral glucose uptake in aged Fischer 344 rats
67. Biochemical effects of ergot alkaloids with special reference to the brain
68. Experimental pathology in basic research of the aging brain
69. Effects of co-dergocrine mesylate (Hydergine®) in multi-in-farct dementia as evaluated by positron emission tomography
70. Relieving select symptoms of the elderly
71. Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine
72. Relation of the electroencephalogram to intellectual function in senescence
73. The effect of treatment on performance and self-appraisal in geriatric patients
74. On the meaning of psychometrically operationalized therapeutic effects in the treatment of brain insufficiency phenomena caused by old age demonstrated by the “Nürnberger-Alters-Inventar”
75. Neurotransmitters, their receptors and the degenerative diseases of the aging brain
76. Habituation of exploratory activity in mice: a screening test for memory enhancing drugs
77. Excitatory effects of Hydergine on intracranial self-stimulation
78. Lack of efficacy of Hydergine in Alzheimer’s disease
79. Changes of pituitary secretion after long-term treatment with Hydergine, in elderly patients
80. Mental decline in the elderly: Pharmacotherapy (Ergot Alkaloids versus Papaverine)
81. Ergoloid-me-sylates (‘Hydergine’) in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial
82. Psychophysiological research in psychiatry and neuropsycho-pharmacology. II. The investigation of antihypoxidotic/noo-tropic drugs (tenilsetam and co-dergocrine-mesylate) in eld-erlies with the Viennese psychophysiological test-system (VPTS)
83. Topographic brain mapping of EEG after acute application of ergotalkalids in the elderly
84. On brain protection of Co-dergocrine mesylate (Hydergine®) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies
85. Serum prolactin changes with age, senile dementia, and dihydroergotoxine mesylate treatment
86. Influence of co-dergocrine on platelet aggregation
87. Ferris S, Gershon S. Psychopharmacology of aging: current trends
88. Treatment of high blood pressure in the elderly with Hydergine®: controlled clinical trial
89. Does the dose play a role?
90. Pharmacokinetic analysis: new methods and results with ergot alkaloids
91. Double blind study of the influence of co-dergocrine on platelet parameters in healthy volunteers
92. Steady state bioavailability of a new oral formulation of Hydergine® in geriatric patients
93. ‘Cerebroactive’ drugs: clinical pharmacology and therapeutic role in cerebrovasular disorders
94. Effects of ergot alkaloids (Hydergine) on cerebral hemodynamics and oxygen consumption in monkeys
95. EEG and clinical effects of diidroergotoxinemethansulphonate in cerebrovascular insufficiency
96. A controlled double-blind study of high-dose dihydroergotox-ine mesylate (Hydergine®) in mild dementia
97. Observations on the brains of demented old people
98. Lack of efficacy of Hydergine in patients with Alzheimer’s disease
99. Observations on the brains of demented old people
100. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine®) in subjects with senile mental deterioration
101. Piracetam: an overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders
102. Multicenter general practitioner trial of Hydergine® in dementia using a screening program — a pilot study
103. Neurophysiological correlates of the intellectual function of elderly persons living in the community
104. Treatment of the classical manifestations of dementia and confusion
105. 2 distribution during oligemic hypotension and its pharmacological modifications
106. Statistical analysis of a study to investigate the efficacy of Hydergine tablets in the long-term treatment of patients with impaired mental and behavioural function and neurosensory disorders
107. Effect of ergot preparation on cognitive ability and depression
108. Design aspects of clinical trials with ergot alkaloids: a comparison of two geriatric behavioral rating scales
109. Vasodilators in senile dementias: a review of the literature